Pharming posts positive leniolisib Phase II topline data in PIDs
Pharming said a late-breaking ESID 2026 abstract will highlight positive Phase II topline data for leniolisib in primary immunodeficiencies with immune dysregulation.
Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, said it has announced a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in gen…